These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25737198)

  • 1. Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates.
    McCluskie MJ; Thorn J; Mehelic PR; Kolhe P; Bhattacharya K; Finneman JI; Stead DR; Piatchek MB; Zhang N; Chikh G; Cartier J; Evans DM; Merson JR; Davis HL
    Int Immunopharmacol; 2015 Apr; 25(2):518-27. PubMed ID: 25737198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates.
    McCluskie MJ; Thorn J; Gervais DP; Stead DR; Zhang N; Benoit M; Cartier J; Kim IJ; Bhattacharya K; Finneman JI; Merson JR; Davis HL
    Int Immunopharmacol; 2015 Dec; 29(2):663-671. PubMed ID: 26404190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice.
    Pryde DC; Jones LH; Gervais DP; Stead DR; Blakemore DC; Selby MD; Brown AD; Coe JW; Badland M; Beal DM; Glen R; Wharton Y; Miller GJ; White P; Zhang N; Benoit M; Robertson K; Merson JR; Davis HL; McCluskie MJ
    PLoS One; 2013; 8(10):e76557. PubMed ID: 24098532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates.
    McCluskie MJ; Pryde DC; Gervais DP; Stead DR; Zhang N; Benoit M; Robertson K; Kim IJ; Tharmanathan T; Merson JR; Davis HL
    Int Immunopharmacol; 2013 May; 16(1):50-6. PubMed ID: 23562759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Physicochemical Modification on the Function of Antibodies Induced by Anti-Nicotine Vaccine in Mice.
    Thorn JM; Bhattacharya K; Crutcher R; Sperry J; Isele C; Kelly B; Yates L; Zobel J; Zhang N; Davis HL; McCluskie MJ
    Vaccines (Basel); 2017 May; 5(2):. PubMed ID: 28513561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of preexisting anti-carrier immunity on subsequent responses to CRM197 or Qb-VLP conjugate vaccines.
    McCluskie MJ; Evans DM; Zhang N; Benoit M; McElhiney SP; Unnithan M; DeMarco SC; Clay B; Huber C; Deora A; Thorn JM; Stead DR; Merson JR; Davis HL
    Immunopharmacol Immunotoxicol; 2016 Jun; 38(3):184-96. PubMed ID: 27121368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.
    Jalah R; Torres OB; Mayorov AV; Li F; Antoline JF; Jacobson AE; Rice KC; Deschamps JR; Beck Z; Alving CR; Matyas GR
    Bioconjug Chem; 2015 Jun; 26(6):1041-53. PubMed ID: 25970207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescreening of Nicotine Hapten Linkers in Vitro To Select Hapten-Conjugate Vaccine Candidates for Pharmacokinetic Evaluation in Vivo.
    Arutla V; Leal J; Liu X; Sokalingam S; Raleigh M; Adaralegbe A; Liu L; Pentel PR; Hecht SM; Chang Y
    ACS Comb Sci; 2017 May; 19(5):286-298. PubMed ID: 28383252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density.
    Zhao Z; Powers K; Hu Y; Raleigh M; Pentel P; Zhang C
    Biomaterials; 2017 Apr; 123():107-117. PubMed ID: 28167389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten Carrier.
    Miller KD; Roque R; Clegg CH
    PLoS One; 2014; 9(12):e114366. PubMed ID: 25494044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence.
    Laudenbach M; Tucker AM; Runyon SP; Carroll FI; Pravetoni M
    Vaccine; 2015 Nov; 33(46):6332-9. PubMed ID: 26409811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probing the protective effects of a conformationally constrained nicotine vaccine.
    Moreno AY; Azar MR; Koob GF; Janda KD
    Vaccine; 2012 Oct; 30(47):6665-70. PubMed ID: 22963803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of a multivalent peptide vaccine for nicotine addiction.
    Zeigler DF; Roque R; Clegg CH
    Vaccine; 2019 Mar; 37(12):1584-1590. PubMed ID: 30772068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localization.
    Zhao Z; Hu Y; Harmon T; Pentel P; Ehrich M; Zhang C
    Biomaterials; 2017 Sep; 138():46-56. PubMed ID: 28551462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.
    Pecetta S; Lo Surdo P; Tontini M; Proietti D; Zambonelli C; Bottomley MJ; Biagini M; Berti F; Costantino P; Romano MR;
    Vaccine; 2015 Jan; 33(2):314-20. PubMed ID: 25448110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers.
    Hatsukami DK; Rennard S; Jorenby D; Fiore M; Koopmeiners J; de Vos A; Horwith G; Pentel PR
    Clin Pharmacol Ther; 2005 Nov; 78(5):456-67. PubMed ID: 16321612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small "Non-Natural" Peptides.
    Le HT; Fraleigh NL; Lewicky JD; Boudreau J; Dolinar P; Bhardwaj N; Diaz-Mitoma F; Montaut S; Fallahi S; Martel AL
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32178357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A conjugate vaccine using enantiopure hapten imparts superior nicotine-binding capacity.
    Lockner JW; Lively JM; Collins KC; Vendruscolo JC; Azar MR; Janda KD
    J Med Chem; 2015 Jan; 58(2):1005-11. PubMed ID: 25493909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negatively Charged Carbon Nanohorn Supported Cationic Liposome Nanoparticles: A Novel Delivery Vehicle for Anti-Nicotine Vaccine.
    Zheng H; Hu Y; Huang W; de Villiers S; Pentel P; Zhang J; Dorn H; Ehrich M; Zhang C
    J Biomed Nanotechnol; 2015 Dec; 11(12):2197-210. PubMed ID: 26510313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of different hapten-carrier conjugation ratios and molecular orientations on antibody affinity against a peptide antigen.
    Pedersen MK; Sorensen NS; Heegaard PM; Beyer NH; Bruun L
    J Immunol Methods; 2006 Apr; 311(1-2):198-206. PubMed ID: 16574142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.